# ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19

> **NCT04393038** · PHASE2,PHASE3 · TERMINATED · sponsor: **Abivax S.A.** · enrollment: 509 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** ABX464
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04393038
- **Lead sponsor:** Abivax S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-01
- **Primary completion:** 2021-03-05
- **Final completion:** 2021-04-16
- **Target enrollment:** 509 (ACTUAL)
- **Why stopped:** Interim analysis concludes that the study is futile
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04393038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04393038, "ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT04393038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*